Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
C. Beneficial Shareholders.
Majorca Group Ltd, 5,200,000 100% Preferred
Majorca Group Ltd. 25,000,000 66.38% Common
Control Person of Majorca: Savannah Matthews
https://www.otcmarkets.com/ajax/showFinancialReportById.pdf?id=174337
that's your control guy
what about the gummy bears? can't leave them out ;-(
I do believe that is exactly what is happening
It is exactly what's happening
i like ben and jerry's better
can we throw in a mining company and a bitcoin deal? lmfao
some need cleaning up for the 150k like a few 8k's and 10q's but the 300k's are spotless and ready to go. let's gather up a few wannabe doctors and go public lol
it once had over a 100m dollar market cap
A shell with a $30MM market cap
i've seen crazier market caps but 30m for a shell is unheard of. i can pick them up all day long between 150-300k
i thought 80c was support. guess not.
anything is possible in this smoking hot penny stock market
Nutra Pharma Corp. ( (NPHC)
0.0028 ? 0.00191 (214.61%)
Volume: 691,044,319 @ 4:01:31 PM ET
Protext Mobility, In (TXTM)
0.0011 ? 0.00021 (23.60%)
Volume: 137,004,385 @ 4:02:19 PM ET
volume explosion towards the close.
poor souls who sold at 0006 and 0007
smart move
rockin now
NO ONE NEEDS THEM. FDBL IS AN EMPTY SHELL
"In the meantime, Protext is taking the necessary steps to align itself with a major U.S. University that is legally empowered to undertake cannabis medicines research, with the goal of eventually submitting an application for an FDA botanical drug claim
http://www.marketwired.com/press-release/protext-pharma-ceo-discusses-south-africa-cannabis-license-otc-pink-txtm-2226072.htm
Protext Pharma CEO Discusses South Africa Cannabis License
www.marketwired.com
BOCA RATON, FL--(Marketwired - Jul 13, 2017) - Protext Pharma, Inc. (OTC PINK: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical botanical medicines that are formulated with highly bioavailable plant extracts, today provided an update with regards to its license application submitted earlier this...
BOCA RATON, FL--(Marketwired - Jul 13, 2017) - Protext Pharma, Inc. (OTC PINK: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical botanical medicines that are formulated with highly bioavailable plant extracts, today provided an update with regards to its license application submitted earlier this year to the South African Government to allow the company to legally grow cannabis and produce non-psychoactive cannabinoid medicines, in that country.
Roger Baylis-Duffield, Chief Executive Officer of Protext Pharma, commented, "Following the submission of our license application earlier this year, officials from the Department Health inspected the company's facilities in May. The 10,000 square foot facility will be used to both grow and harvest the live cannabis and to produce a formulated cannabinoid complex. Our application and all supporting documents were reviewed by the Portfolio Committee during the first week of July, 2017. Subsequent to that review, the Department of Health requested additional details regarding production schematics, operational protocols and product distribution. The Company intends to submit these final requests this week and we believe that the license will be granted imminently."
Once the license is issued, Protext will commence setting up its grow facility where plants can be cloned and cultivated to ensure a consistent chemical profile. An on-site extraction laboratory will take the live plant material and produce a cannabis complex containing the full profile of all the phytonutrients, including cannabinoids, terepenes, cannabinoid acids and polyphenols. Based on parent-company Plandaí's clinically-proven science, the resulting complex is anticipated to contain the full profile of cannabinoids, including the precursor acids THC-A and THC-B together with CBD, in a non-psychoactive extract. Once the first plant extract is produced, it will be subjected to extensive chemical profiling in addition to tests to confirm its bioavailability, ability to cross the blood brain barrier, and lack of psycho-activity. Mr. Duffield added, "After our application is issued, Protext will be one of a few companies in the world legally allowed to conduct research and development and produce cannabis medicines. Part of our business model will be working with the government of South Africa to develop cannabis medicines with an objective of having our extract declassified from a Level 6 controlled substance to a Level 0 controlled medicine, based on non-psychoactivity. This declassification should help facilitate our selling the product throughout the world."
"In the meantime, Protext is taking the necessary steps to align itself with a major U.S. University that is legally empowered to undertake cannabis medicines research, with the goal of eventually submitting an application for an FDA botanical drug claim. These defined studies will establish anti-inflammatory activities with cannabinoid receptors in order to develop Protext's non-psychoactive medicines for specific arthritis therapies. These investigations are intended to further establish the therapeutic benefits through the suppression and containment of inflammation in human cells and are expected to establish improved activity by the slowing of degradation in affected joints and the reduction of both pain and disability. Arthritis is the most common cause of disability in the US. More than 20 million individuals with arthritis have severe limitations in function on a daily basis. It is estimated that the total cost of arthritis cases is close to $100 billion of which almost 50% is from lost earnings. Each year, arthritis results in nearly 1 million hospitalizations and close to 45 million outpatient visits to health care centers. Our proposed cannabinoid anti-inflammatory drug has the potential to deliver products with lesser side effects and better efficacy over current drug regimens," concluded Mr. Duffield.
Investors are encouraged to follow Protext using:
YouTube: http://bit.ly/ProtextYouTube
Twitter: https://twitter.com/protxtm
Instagram: https://www.instagram.com/protextm/
About Protext Pharma, Inc.
Protext Pharma operates two wholly owned subsidiaries; Plandai Biotechnology South Africa (Pty) Ltd. and Cannabis Biosciences, Inc. The Company is engaged in the research, clinical testing and commercialization of highly bioavailable botanical products -- all natural ingredients formulated for pharmaceutical applications and produced under pharma-grade conditions. Please visit http://www.protextm.co for further information.
About Plandai Biotechnology SA
Through its wholly owned subsidiary Plandai Biotechnology SA (OTC PINK: PLPL), the Company has the exclusive worldwide license to develop Phytofare® extracts from live plant materials including Phytofare® catechin complex, a highly bioavailable, and clinically proven antioxidant complex produced from live green tea leaves. Phytofare® can deliver a therapeutic level of catechins, which function as powerful antioxidants, to the system where they remain active for over 24 hours.
About Cannabis Biosciences
The Company is actively pursuing government licensing that will allow it to use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential and having the heightened bioavailability of other Phytofare® extracts.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.
CONTACT INFORMATION
CONTACT INFORMATION
Protext Pharma, Inc.
Info@protextm.co
Contact: (435) 881-3611
trips are a gift. finally a real penny stock company
like i said it's a real deal. something you can touch, feel, visit and he actually eat. lol . no p.o boxes here
yessir. hearing big corporate developments in the works. expansion, franchising, etc, etc. knsc is the real deal. no p.o boxes here lol
Sure is quite for such a big day.
that will change soon bro.
From all indications these restaurants are real lol
i been there. the place is jammed packed. a lot of hotties too lol
or maybe just one lammy but it cost as much as 10
https://www.lamborghini.com/en-en/models/one-off/veneno-roadster
on that note i am ordering 10 lambo's LOL
sweet run so far. real co, real assets and real earnings. hearing big expansion coming too. the next benihana's ???
sweet run from 000x0001 a few months ago to 001. wow weeeeeeeeeeeeeeeeeeeeeeeeeeeee
an update would be nice
Protext Mobility, In (TXTM)
0.0007 ? 0.00005 (7.69%)
Volume: 32,561,515 @ 3:02:12 PM ET
we need an update on the license like yesterday. we did bounce off 0006 to hit 0009.
hopefully we will get an update on the license very soon. hearing good things
the only 2 positive things see here is it's holding the 80's and there's like hardly any float so any major news (no fluff bs) could send this stock on tear. i watched kbio go from 1.00 to 45.00 in a week when martin shkreli joined but only to crash back back down to 1.00 after his legal issues so anything is possible here
Blue Apron closes at new low after analyst slaps on $2 price target
Northcoast Research released a note recommending clients sell Blue Apron stock, placing the target price at $2 a share.
Shares have fallen more than 20 percent month to date.
Anita Balakrishnan | @MsABalakrishnan
1 Hour Ago
CNBC.com
Traders work on the floor of the Exchange ahead of the Blue Apron IPO on the New York Stock Exchange in New York, June 29, 2017
Lucas Jackson | Reuters
Traders work on the floor of the Exchange ahead of the Blue Apron IPO on the New York Stock Exchange in New York, June 29, 2017
Tuesday was another crushing day for Blue Apron on Wall Street.
Shares fell more than 12 percent, hitting a new closing low of $7.14 a share, just above the all-time intraday low of $7.08 a share. The move lower came after Northcoast Research released a note recommending clients sell the stock, placing the target price at $2 a share.
The note from analyst Chuck Cerankosky marked one of the first formal reactions to Blue Apron's June IPO from a Wall Street analyst. Shares have fallen more than 20 percent month to date, amid jitters surrounding the company's valuation and a merger between Amazon and Whole Foods.
"Our financial outlook for the company is one of continued losses," Cerankosky said. "Sales growth seems to be dependent at this time upon promotional discounts."
Blue Apron, backed by First Round Capital, SG Growth Partners and Bessemer Venture Partners, lost nearly as much money in the first quarter of 2017 ($52 million, on quarterly revenue of $244 million) as it did in all of 2016 (when it lost $55 million on $795 million in revenue).
Despite investments from technology investors, Cerankosky wrote that Blue Apron "is not a technology company just because orders are received digitally," pointing to its labor-intensive assembly process for each meal kit. Blue Apron might not become profitable even in Cerankosky's model of a best-case scenario for the company.
Still, Blue Apron said in IPO filings that the company relies "on our proprietary technology and data to forecast demand and predict our customers' orders [and] determine the amounts of ingredients and other supply to purchase." That, the company says, will make it more efficient over time.
Many more analysts are likely to share their opinions on the company in the coming weeks, and may or may not agree with Cerankosky.
"When you have a company that's not making money, the anchor for its valuation is very weak," Kathleen Smith, principal at Renaissance Capital, a manager of IPO-focused ETFs, told CNBC last week.
Anita Balakrishnan
Anita Balakrishnan
News Associate
http://www.cnbc.com/2017/07/11/blue-apron-aprn-hits-52-week-low-after-northcoast-capital-note.html
hope the boys don't run into anymore issues
read it careful boys. i am all over it and already forwarded it to certin peeps. sleep night guys. like you don't enuff to worry about
Accumulate down here for the big push next month.
make some damn calls and get those 0002's taken out LOL
GM TO EVERYONE
stay tuned
Wrong. WOODLAND is a spinoff from CWRL.